Periscope Capital Inc. Has $3.42 Million Stock Holdings in Oaktree Acquisition Corp. III Life Sciences $OACC

Periscope Capital Inc. lowered its position in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) by 19.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 323,400 shares of the company’s stock after selling 76,600 shares during the quarter. Periscope Capital Inc.’s holdings in Oaktree Acquisition Corp. III Life Sciences were worth $3,422,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of OACC. Goldman Sachs Group Inc. acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the first quarter worth $5,417,000. Moore Capital Management LP acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the second quarter worth $5,502,000. Millennium Management LLC acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the first quarter worth $4,848,000. Lighthouse Investment Partners LLC lifted its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 88.9% during the second quarter. Lighthouse Investment Partners LLC now owns 850,000 shares of the company’s stock worth $8,882,000 after buying an additional 400,000 shares in the last quarter. Finally, Sculptor Capital LP lifted its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 100.0% during the second quarter. Sculptor Capital LP now owns 500,000 shares of the company’s stock worth $5,225,000 after buying an additional 250,000 shares in the last quarter.

Oaktree Acquisition Corp. III Life Sciences Price Performance

OACC opened at $10.68 on Friday. Oaktree Acquisition Corp. III Life Sciences has a fifty-two week low of $10.30 and a fifty-two week high of $10.74. The stock has a fifty day moving average of $10.66 and a 200-day moving average of $10.64.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last issued its quarterly earnings results on Thursday, March 26th. The company reported $0.08 EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a report on Thursday, April 2nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Oaktree Acquisition Corp. III Life Sciences has an average rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Profile

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.